REMARKS

Claims 1-12 and 49-63 are now pending in this application and are all method claims.

Respectfully submitted,



Richard J. Traverso (Reg. No. 30,595)
Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Boulevard, Suite 1400
Arlington, Virginia 22201
(703) 812-5310 [Direct Dial]
E-mail address: traverso@mwzb.com

Filed: March 4, 2002

RJT/lvb
K:\Bayer\16p2\prel amend 3-4-02.wpd

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION

Please amend page 85, third paragraph as follows.

Entry 101: ~~4-Chloro-N-methyl-2-pyridinecarboxamide, which was synthesized according to Method A2, Step 3a, was reacted with 3-aminophenol according to Method A2, Step 4, to form 3-(-2-(*N*-methycarbamoyl)-4-pyridyloxy)aniline.~~ 2-Amino-3-methyoxynaphthalene was synthesized as described in Method A1. According to Method C3, 2-amino-3-methoxynaphthalene was reacted with bis(trichloromethyl) carbonate followed by ~~3-(-2-*N*-methylcarbamoyl)-4-pyridyloxy)aniline~~ an aniline to form the urea.

IN THE CLAIMS

Claims 13-48 have been canceled without prejudice or disclaimer.

Claim 6 has been amended as follows.

6. (Amended) A method as in claim 1 wherein the condition within a host treated by administering a compound of formula I is ~~an~~ an infectious disease selected from the group consisting of tuberculosis, Helicobacter pylori infection during peptic ulcer disease, Chaga's disease resulting from Trypanosoma cruzi infection, effects of Shiga-like toxin resulting from E. coli infection, effects of enterotoxin A resulting from Staphylococcus infection, meningococcal infection, and infections from Borrelia burgdorferi, Treponema pallidum, cytomegalovirus, influenza virus, Theiler's encephalomyelitis virus, and the human immunodeficiency virus (HIV).

RJT/lvb
K:\Bayer\16p2\prel amend 3-4-02.wpd